tradingkey.logo

Virax Biolabs Group Ltd

VRAX
查看詳細走勢圖
0.227USD
+0.004+2.03%
收盤 02/06, 16:00美東報價延遲15分鐘
1.48M總市值
虧損本益比TTM

Virax Biolabs Group Ltd

0.227
+0.004+2.03%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.03%

5天

-19.93%

1月

-38.42%

6月

-71.09%

今年開始到現在

-34.47%

1年

-86.75%

查看詳細走勢圖

TradingKey 股票評分

由於缺少必要的數據,暫時無法對該公司進行評分

Virax Biolabs Group Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Virax Biolabs Group Ltd簡介

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
公司代碼VRAX
公司Virax Biolabs Group Ltd
CEOFoster (James)
網址https://www.viraxbiolabs.com
KeyAI